

**National Oncology Conference
BJCN-MORÉ 2023**

**Management of Esophageal
and Gastroesophageal Junction Carcinoma
Tele-oncology and BJCN Cluster Interactions**

9 – 12 November 2023

SCIENTIFIC PROGRAM

November 9, 2023, Thursday

17:00 – 17:20 Official opening

Annual Award *BJCN-MORÉ* – for contribution to Bulgarian clinical oncology

17:20 – 18:20 Symposium *BMS*

**Gastro-Esophageal Cancer and Immuno-Oncology Today: Best Practice and
Clinical Challenges**

Chairman: *Assoc. Prof. Dr. A. Konsoulova*

17:20 – 17:40 Biomarker overview in upper gastrointestinal (uGI) cancers
Prof. Dr. S. Popovska

17:40 – 18:00 Current treatment options in uGI cancers
Dr. M. Koleva

18:00 – 18:10 Case presentations
Dr. K. Koynov

18:10 – 18:20 Discussion

18:25 – 19:45 *Varia*

Chairman: *Prof. Dr. J. Grudeva*

18:25 – 18:45 Place of *Lumikras* in patients with non-small cell lung cancer (NSCLC)
Dr. V. Kanarev, Amgen

18:45 – 19:05 First-line treatment with *avelumab* in advanced or metastatic
urothelial carcinoma – already two years in Bulgaria
Assoc. Prof. Dr. A. Konsoulova, Merck

19:05 – 19:15 First-line therapy with *Kisqali* prolongs survival in metastatic breast
carcinoma

Assoc. Prof. Dr. A. Konsoulova, Novartis

19:15 – 19:25 Do patients with metastatic breast carcinoma and aggressive visceral disease need first-line chemotherapy

Dr. K. Koynov, Novartis

19:25 – 19:45 Current therapeutic options for the treatment of metastatic hormone-sensitive prostate cancer – role of *apalutamide* in the treatment algorithm

Dr. R. Mangaldjiev, Johnson & Johnson

19:45 – 20:05 *Verzenio*: a new approach in the treatment of HR+, HER2- early CG – in patients with axillary lymph node involvement, at high risk of relapse

Assoc. Prof. Dr. A. Konsoulova, Eli Lilly

20:30 Welcome dinner



November 10, 2023, Friday

08:00 – 10:50 FIRST PLENARY SESSION

Pretherapeutic and diagnostic issues in esophageal and gastroesophageal junction (GJC) carcinoma

Chairman: *Prof. Dr. D. Toncheva*

08:00 – 08:15 Update on the GRADE approach

Assoc. Prof. Dr. D. Kalev

08:20 – 08:40 Genetic architecture of esophageal carcinoma

Prof. Dr. D. Toncheva

08:45 – 09:05 Liquid biopsy as a method of diagnosis, prognosis and prediction

Assoc. Prof. M. Georgieva

09:10 – 09:30 Value of screening endoscopy and target population in esophageal carcinoma and GJC: how early detection and prevention strategies can be improved

Dr. Z. Gorcheva, Assoc. Prof. Dr. P. Karagyozov

09:35 – 09:55 Cellular and molecular drivers in *Barrett's* esophagus and adenocarcinoma

Assoc. Prof. Dr. S. Bachurska

10:00 – 10:20 Clinical significance of the microbiome in upper gastrointestinal carcinomas

Dr. M. Koleva

10:25 – 10:45 Benefits, pitfalls, and artificial intelligence (AI) in hybrid imaging of esophageal carcinoma

Prof. Dr. E. Piperkova, Dr. L. Chavdarova, Prof. Dr. I. Kostadinova

10:50 – 11:10 Coffee break

11:10 – 13:35 SECOND PLENARY SESSION

Surgical strategies in esophageal and gastroesophageal junction carcinoma

Chairman: *Prof. Dr. I. Takorov*

11:10 – 11:30 Endoscopic control of early esophageal carcinoma and GJC – pitfalls and outcomes

Assoc. Prof. Dr. A. Katzarov

11:35 – 11:55 Traditions and modifications in the *Ivor Lewis* esophagectomy technique

Assoc. Prof. Dr. N. Belev

12:00 – 12:40 *Ivor Lewis* steps in minimally invasive and robotic esophagectomy and protocols for three-field *McKeown* esophagectomy

Assoc. Prof. Dr. Tz. Minchev

12:45 – 13:05 Transhiatal esophagectomy

Prof. Dr. D. Kostov, Dr. J. Kalcheva

13:10 – 13:30 Liver metastases from esophageal carcinoma – is there a role for surgical resection

Dr. R. Kostadinov, Dr. Tz. Trichkov, Assoc. Prof. Dr. V. Mihailov, Prof. Dr. N. Vladov

13:35 – 14:30 Lunch

14:30 – 16:10 THIRD PLENARY SESSION

Problems of perioperative approaches in esophageal and gastroesophageal junction carcinoma

Chairman: *Assoc. Prof. Dr. V. Ivanova*

14:30 – 14:50 Classification of pathologic response from neoadjuvant therapy in esophageal carcinoma and GJC

Assoc. Prof. Dr. I. Ivanov

14:55 – 15:15 Imaging biomarkers in the treatment of esophageal carcinoma

Assoc. Prof. Dr. V. Stoyanova, Dr. N. Mladenova, Prof. Dr. G. Kirova

15:20 – 15:40 Prediction of pCR and detection of residual disease in neoadjuvant chemoradiotherapy for esophageal carcinoma

Assoc. Prof. Dr. V. Ivanova

15:45 – 16:05 The unusual patient with ypT0N+ esophageal carcinoma – what's next
Assoc. Prof. Dr. N. Chilingirova

16:10 – 16:30 Coffee break

16:30 – 17:30 Symposium MSD

Implementation of pembrolizumab treatment strategies in clinical practice

Chairman: *Assoc. Prof. Dr. D. Kalev*

16:30 – 16:40 Opening remarks

16:40 – 17:00 First-line *pembrolizumab* combination therapy in patients with metastatic non-small cell lung cancer – one patient, two diagnoses and many questions

Dr. K. Koynov

17:00 – 17:20 Triple negative breast cancer – from clinical studies to real practice
Assoc. Prof. Dr. A. Konsoulova

17:20 – 17:30 Discussion

17:35 – 18:40 DISCUSSION SESSION

Expert discussion Pros/Cons

Chairman: *Prof. Dr. T. Hadjieva*

17:35 – 17:55 Management of T1b esophageal carcinoma: endoscopic resection versus esophagectomy

Assoc. Prof. Dr. P. Karagyozov vs. Assoc. Prof. Dr. N. Belev

17:55 – 18:15 Neoadjuvant therapy in esophageal adenocarcinoma and GJC: chemotherapy versus radiochemotherapy

Dr. M. Koleva vs Prof. Dr. T. Hadjieva

18:15 – 18:35 Treatment of locally advanced esophageal squamous cell carcinoma: definitive radiochemotherapy versus neoadjuvant radiochemotherapy followed by surgery

Dr. K. Yordanov vs. Dr. K. Nedev

18:45 – 19:45 Symposium AstraZeneca

Innovation in the near future

Chairman: *Assoc. Prof. Dr. A. Konsoulova*

18:45 – 19:05 What's new on the horizon in the treatment of HER2-negative early breast cancer and metastatic castration-resistant prostate cancer (mCRPC)

Dr. R. Mangaldjiev


19:05 – 19:25 Unfolding the spectrum of options in the treatment of advanced HER2-positive gastric cancer

Dr. M. Koleva

19:25 – 19:45 Breakthrough of immunotherapy in the treatment of unresectable or metastatic bile ducts carcinoma (BDC)

Dr. M. Koleva

20:00 Dinner



November 11, 2023, Saturday

08:00 – 10:05 **FOURTH PLENARY SESSION**

Systemic, radiotherapy and palliative strategies in esophageal and gastroesophageal junction carcinoma

Chairman: *Prof. Dr. M. Genova*

08:00 – 08:20 Sensitivity of hematologic markers in patients receiving therapy for esophageal carcinoma

Prof. Dr. M. Genova, Prof. Dr. G. Balatzenco

08:25 – 08:45 Targets in systemic therapy in esophageal carcinoma and GJC

Dr. R. Mangaldjiev

08:50 – 09:10 Integration of immunotherapy across all lines of treatment in esophageal carcinoma and GJC – prediction with PD-L1, MSI, and TMB

Assoc. Prof. Dr. A. Konsoulova

09:15 – 09:35 Chemoradiation in oligometastatic disease from esophageal carcinoma

Prof. Dr. T. Hadjieva, Dr. M. Koleva

09:40 – 10:00 Effect of early nutritional support on clinical outcomes in esophageal carcinoma

Assoc. Prof. Dr. N. Yordanov

10:05 – 10:25 **Comprehensive genomic profiling**

Clinical value of comprehensive genomic profiling with Foundation Medicine in lung cancer patients

Dr. M. Koleva

10:25 – 10:55 Coffee break

10:55 – 11:55 **Symposium Pierre Fabre**

Chairman: *Assoc. Dr. D. Kalev*

10:55 – 11:00 Opening remarks

11:00 – 11:25 Clinical challenges in metastatic colorectal carcinoma (mCRC) with BRAF V600E mutation, targeted therapy with the *encorafenib* & *cetuximab* combination

Dr. P. Balikova

11:25 – 11:50 *Encorafenib* & *binimetinib* treatment of unresectable or metastatic melanoma with BRAF V600 mutation

Dr. G. Shalamanova

11:50 – 11:55 Discussion

12:00 – 13:00 Symposium Pfizer

Science meets practice for a better tomorrow for patients with HR+/HER2- metastatic breast cancer (mBC)

Chairman: *Assoc. Dr. A. Konsoulova*

12:00 – 12:20 After eight years of experience and evidence – increasingly confident in the treatment of HR+/HER2- mBC in a wide range of patients

Dr. K. Koynov

12:20 – 12:40 The real practice in the treatment of HR+/HER2- mBC through the perspective of local clinical experience

Dr. K. Nikolov

12:40 – 13:00 Discussion

13:00 – 14:00 Lunch

14:00 – 14:40 Symposium Roche

Chairman: *Dr. R. Mangaldjiev*

14:00 – 14:05 Opening remarks

14:05 – 14:25 *Phesgo* benefits for patients and healthcare professionals beyond efficacy – an example from real clinical practice

Assoc. Prof. Dr. A. Konsoulova

14:25 – 14:40 Change in the standard of care in non-small cell lung carcinoma (NSCLC) early stage

Dr. V. Minchev

14:45 – 15:40 FIRST BJCN JOINT SESSION

Integrative Oncology

Chairman: *Dr. P. Zagorchev*

14:45 – 15:05 Possibilities of homeopathy in the integrative approach in oncological patients

Dr. J-L Bagot

15:05 – 15:15 My experience in complementary treatment in cancer patients

Dr. P. Zagorchev

15:15 – 15:25 Possibilities of homeopathy to support the cancer patient in the general practitioner's office

Dr. I. Enev

15:25 – 15:40 Discussion

15:45 – 16:25 SECOND BJCN JOINT SESSION

Cluster interaction potentials in BJCN: multipliers, mutual benefits and ecosystem effects

Chairman: *Assoc. Prof. Dr. D. Kalev*

15:45 – 15:50 Welcome and introductions

15:50 – 16:05 Projects with the participation of BJCN - presentation with perspectives
I. Petrov

16:05 – 16:20 BJCN programs for continuing medical education in oncology and oncohematology

Prof. Dr. M. Genova

16:20 – 16:25 Discussion

16:25 – 16:45 Coffee break

16:45 – 19:45 THIRD BJCN JOINT SESSION

Tele-oncology in the social triangle – research, technologies, and policies Part I: Keynote panel

Chairmen: *I. Cattaneo*

*European Federation of Pharmaceutical Industries and Associations
(EFPIA)*

I. Petrov, BJCN

16:45 – 16:50 Welcome and introductions

16:50 – 17:05 Uniting against Cancer: ECHoS Project

Y. Fonseca

Agency for Clinical Research and Biomedical Innovation (AICIB), Portugal

17:05 – 17:20 Innovation in Cancer Primary Prevention – The 4P-CAN Project

Dr. M. Geantă, B. Cucuș

Centre for Innovation in Medicine (InoMed), Romania

17:20 – 17:35 Comprehensive Cancer Infrastructures

E. Griesshammer, German Cancer Society

17:35 – 17:50 eCAN – A Joint Action of 16 EU Member States for strengthening telemedicine in cancer care

T. Schmitt, K. Habimana

Strengthening eHealth for Cancer Prevention and Care (eCAN Joint Action)

17:50 – 18:05 Digital solutions for monitoring patient symptoms and adverse drug events

Prof. Dr. G. Velikova, University of Leeds, UK

18:05 – 18:15 The point of view of a Cancer center General Manager

Dr. V. Daskalov, National Oncology Hospital – Bulgaria

18:15 – 18:20 Concluding remarks

Part II: Discussion panel

Chairmen: Dr. A. Simidchiev

Assoc. Dr. D. Kalev


18:20 – 18:25 Welcome and introductions

18:25 – 19:25 Action-oriented discussion

With representatives from: Ministry of Health, Ministry of Innovation and Growth, Medical University of Pleven, National Oncology Hospital – Bulgaria, Municipality of Varna, Bulgarian Cluster for Digital Solutions and Innovations in Health Care, National Patient Organization, *Junior Achievement* Bulgaria, Law Office *Murgova and Partners*, BJCN

19:25 – 19:45 Memorandum and concluding remarks

20:00 Dinner



November 12, 2023, Sunday

08:30 – 10:00 **FOURTH BJCN JOINT SESSION**

Health technologies panorama in Bulgarian oncology

Chairman: *I. Lekushev*

08:30 – 08:40 Referendo – digital platform for patient referendum

R. Dimitrov, B-eye

08:40 – 08:50 A revolution in cervical cancer screening

P. Prandzhev, GYNie.ai

08:50 – 09:00 Digital technologies to empower care and cross-border research in oncology

E. Syundyukov, Medical technology startup company Longenesis, Riga, Latvia

09:00 – 09:10 A digital platform for real-world data analysis

D. Taneva, MYSynergy

09:10 – 09:20 MOPE e-Guidelines – from the GRADE approach to AI

I. Lekushev, I. Dragoeva, BGO Software

09:20 – 09:30 Bringing sponsors, investigators, and research sites through the digital application 'FIND MORE'

M. Jekov, Sqilline

09:30 – 09:40 Discover PrOPA – one story by *Shemha Health*

I. Petrov, Shemha Health

09:40 – 10:00 Discussion

10:00 – 10:15 Coffee break

10:15 – 12:15 JOINT BJCN ROUND TABLE

BJCN Cluster interaction – Capacity building

Chairman: *Assoc. Dr. D. Kalev*

With the participation of representatives from all BJCN members organizations

12:15 – 12:30 Official closing

12:30 Lunch